Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

Table 2 Changes in clinical data of patients after treatment in the two groups

	Rifaximin group (n = 50)			Control group (n = 25)			P value
	d0	d15	mean delta	d0	d15	Mean delta
Weight (kg)	70.00 (60.00-78.75)	69.00 (58.00-74.00)	-3.30	62.00 (55.00-71.25)	59.5 (54.88-59.5)	-1.20	0.011
Cr (μmol/L)	70.20 (57.00-93.53)	78.25 (63.10-92.68)	11.82	9 (8.00-11.00)	73.0 (63.35-95.65)	13.54	0.777
Urea (mmol/L)	7.17±4.70	9.07±6.71	1.90	8 (5.50-10.00)	7.63±3.31	0.95	0.258
eGFR (mL/min 1.73 m2)	95.49 (76.17-114.81)	93.11 (71.92-108.00)	-5.20	98.80 (86.80-109.37)	92.0 (61.59-99.54)	-9.68	0.136
Child-Pugh score	10 (8.00-11.25)	9 (8.00-10.25)	-0.90	9 (8.00-11.00)	8 (7.50-10.50)	-0.76	0.666
MELD score	10 (6.00-13.00)	11.5 (6.75-15.25)	0.60	8 (5.50-10.00)	8 (6.50-10.00)	0.92	0.688

Delta was defined as the value after treatment minus the value before treatment. eGFR: Estimate glomerular filtration rate; MELD: Model for end-stage liver disease.